Dendrimer-RGD Conjugation Service

Arginine-glycine-aspartic acid (RGD) peptides linked to dendrimers can be used as a carrier platform for drug encapsulation and targeting of cancer cells to achieve disease treatment. CD BioSciences has advanced facilities and experienced scientists to provide high quality RGD binding to dendrimers.

Integrins and RGD

Integrin proteins, a member of the cell surface receptor family, are overexpressed on the surface of cancer cells and are promising targets for macromolecular drugs and gene delivery for the treatment of cancer. Among them, αvβ3 integrins are well known for their role in cancer progression and are overexpressed in melanoma, glioblastoma, ovarian, breast and prostate cancer cells. Arginine-glycine-aspartic acid (RGD) peptides are the most common peptides responsible for cell adhesion to the extracellular matrix (ECM), are present in various species, interact with integrins with high affinity and are widely used as ligands for targeted drugs and gene delivery vectors.

Dendrimer-RGD Conjugation

In addition to applications in the chemical industry, dendrimers and their composites have made important advances in biomedical applications, including drug delivery, gene delivery, and MRI agents. Dendrimers are biocompatible, non-immunogenic, and easily introduce various chemical groups at the terminal and central positions. When combined with RGD peptides, dendrimers can target tumor cell surface integrins and mediate cell binding and adhesion to drugs for therapeutic or targeted delivery of imaging agents for more accurate cancer diagnosis.

Synthesis of RGD-PEG-PAMAM conjugates. (Chen Z, et al., 2016)

Applications of Dendrimer-RGD Conjugation

RGD peptide-based dendrimers are widely used in biological research and medical devices, not only as multifunctional "smart" delivery materials, such as carriers for targeted drugs and imaging agents for targeted tumor cells, but also for tissue engineering to promote tissue regeneration.

• Drug Delivery/Imaging Agent Delivery
  Dendrimers bound to RGD peptides act as nanocarriers to target drugs to specific cells, particularly cancer cells that overexpress integrin αvβ3. In addition, imaging agents targeting tumor cells can be delivered to enable more accurate diagnosis of cancer.

• Gene Delivery
  RGD has been combined with a non-viral vector dendrimer to allow targeted delivery of genetic material to target cells, thereby improving transfection efficiency.

• Tissue Engineering
  As a ligand for ECM, RGD can control cellular responses to biological materials, such as attachment, proliferation, and differentiation. RGD-modified vascular tissue grafts can inhibit platelet adhesion, improve cell infiltration, and enhance endothelialization. Addition of RGD to cardiac scaffolds promotes cell adhesion, prevents apoptosis, and enhances tissue regeneration. RGD-coated bone tissue grafts can improve bone cell adhesion, proliferation, and survival. RGD can also be used for regeneration of retinal pigment epithelium.

Our Services

As a fast growing and leading global provider of scientific research services and solutions, CD BioSciences offers you dendrimer-RGD conjugation services. We are committed to meeting all your detailed requirements and guarantee that all deliverables are subjected to rigorous quality testing.

Service Process

CD BioSciences is committed to helping our customers meet the growing and evolving demand for dendrimers products. We offer a wide range of services related to dendrimers and ensure quality and reliability of results as well as on-time delivery. If you are interested in our services or have any additional questions, please feel free to contact us, we are happy to hear from you and look forward to working with you.

Reference

1. Chen Z.; et al. Arginine-glycine-aspartic acid-polyethylene glycol-polyamidoamine dendrimer conjugate improves liver-cell aggregation and function in 3-D spheroid culture. Int J Nanomedicine. Int J Nanomedicine. 2016, 11: 4247-59.